Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease?
Interventions targeting the serum eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio could be useful for the prevention of coronary artery disease (CAD). Few data exist regarding the effects of administration of EPA on the serum levels of soluble thrombomodulin (sTM) as a marker of endothelial damage, or on the relationship between the sTM and EPA/AA ratio in patients with CAD receiving statin treatment. We assigned stable CAD patients already receiving statin therapy to an EPA group (1800 mg/day: n = 50) or control group (n = 50). A significant increase of the sTM level was observed in the EPA group as compared to that in the control group 0.40 (0.10/0.70) FU/mL vs. 0.20 (0/0.40) FU/mL, p = 0.004 at the 6-month follow-up examination. Multivariate regression analysis after adjustments for coronary risk factors and changes of the serum lipid levels identified an increased EPA/AA ratio as an independent predictor of increased serum sTM level (β = 0.244, p = 0.02). The results suggest that an increased sTM level caused by additional administration of EPA to statin might be associated with an increased EPA/AA ratio. The increase of the serum sTM after administration of EPA might reflect an increase of the TM expression on the endothelial surface rather than endothelial damage in CAD patients under statin treatment.
Clinical Trial Registration Information UMIN (http://www.umin.ac.jp/), Study ID: UMIN000010452.
KeywordsEicosapentaenoic acid Soluble thrombomodulin Vascular endothelial cell
This work was supported by KAKENHI Grant number 23590757 of the Japan Society for the Promotion of Science (JSPS). The authors would like to thank International Medical Information Center (www.imic.or.jp/services/translation.html) for the English language review. The authors would also like to thank Mr. Gary Cooper for his help in editing the English manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369:1090–1098CrossRefGoogle Scholar
- 4.Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y, Investigators JELIS (2011) Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb 18:99–107CrossRefGoogle Scholar
- 5.Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, Yamamoto M, Shinozaki T, Miyauchi K, Nagao K, Hirayama A, Yoshimura M, Komuro I, Nagai R, Daida H (2014) Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. Am J Cardiol 113:441–445CrossRefGoogle Scholar
- 6.Tani S, Nagao K, Kawauchi K, Yagi T, Atsumi W, Matsuo R, Hirayama A (2017) The ratio of eicosapentaenoic acid (EPA) to arachidonic acid may be a residual risk marker in stable coronary artery disease patients receiving treatment with statin following EPA therapy. Am J Cardiovasc Drugs 17:409–420CrossRefGoogle Scholar
- 7.Takahashi M, Ando J, Shimada K, Nishizaki Y, Tani S, Ogawa T, Yamamoto M, Nagao K, Hirayama A, Yoshimura M, Daida H, Nagai R, Komuro I (2017) The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study. BMC Cardiovasc Disord 17:41CrossRefGoogle Scholar
- 12.Califano F, Giovanniello T, Pantone P, Campana E, Parlapiano C, Alegiani F, Vincentelli GM, Turchetti P (2000) Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci 4:59–66Google Scholar
- 16.Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK (1999) Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353:1729–1734CrossRefGoogle Scholar
- 19.Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA (2001) AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 38:1581–1583CrossRefGoogle Scholar
- 20.Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50CrossRefGoogle Scholar
- 22.Lin SJ, Hsieh FY, Chen YH, Lin CC, Kuan II, Wang SH, Wu CC, Chien HF, Lin FY, Chen YL (2009) Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFalpha-treated human aortic endothelial cells. Histol Histopathol 24:1147–1159Google Scholar
- 23.Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14:575–585CrossRefGoogle Scholar
- 24.Wu KK, Matijevic-Aleksic N (2000) Thrombomodulin a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis. Ann Med 32(Suppl 1):73–77Google Scholar
- 28.Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I (2013) Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol 111:6–11CrossRefGoogle Scholar
- 30.Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Verveniotis A, Plastiras A, Kioufis S, Maniatis K, Miliou A, Siasou Z, Stefanadis C, Papavassiliou AG (2013) Effects of Ω-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: a cross over study. Int J Cardiol 166:340–346CrossRefGoogle Scholar